Our drug candidates inhibit the oncology targets BTK, RAF dimer and PARP, and have demonstrated early activity and favorable safety profiles.
Our lead immuno-oncology drug candidate inhibits the target PD-1, and is currently in a Phase 1 dose-escalation trial.
Our cancer biology platform allows us to evaluate and develop rational combinations of immuno-oncology and targeted cancer therapies.
Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. Our proximity to leading cancer centers in Beijing and close relationships with clinicians have allowed us to develop an extensive collection of in vivo, ex vivo and in vitro models, enabling our research team to better select targets, screen and evaluate therapeutic agents we believe have significant potential alone or in combination to be best- or first-in-class treatments for a variety of cancers.
We have a global team of 215 individuals, including 149 scientists and clinicians, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world.